

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kevin M. Slawin et al.	Examiner:	Russell Scott Negin
Serial No.:	10/071,861	Group Art Unit:	1631
Filed:	February 07, 2002	Docket:	675.002US1
Title:	METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants hereby authorize the Commissioner to charge the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p), to Deposit Account No. 19-0743. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification of this change to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

KEVIN M. SLAWIN ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

September 5, 2006

By

Janet E. Embretson
Reg. No. 39,666

CERTIFICATE UNDER 37 C.F.R. 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this

5 day of September 2006.

Name

John D. Gieske-Kluth

Signature

John D. Gieske-Kluth

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/071,861
Filing Date	February 7, 2002
First Named Inventor	Slawin, Kevin
Group Art Unit	1631
Examiner Name	Negin, Russell

Sheet 1 of 1

Attorney Docket No: 675.002US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-6,960,449	11/01/2005	Wang, Zheng-Pin , et al.	02/10/2000

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Y ²
	WO-0063841A1	10/26/2000	Wilkinson, L.	
	WO-9938011A1	07/29/1999	Pollack, M. N., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
		DJAKIEW, D. , "Dysregulated Expression of Growth Factors and Their Receptors in the Development of Prostate Cancer", <u>The Prostate</u> , 42, (2000),150-160	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1448)

* EXAMINER: Initial if reference considered, whether or not effective in accordance with MPEP 806. Draw line through status if not in accordance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is placed in the space provided here if English language Translation is attached.